Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This multimodal analgesic intervention, developed by the University of British Columbia, is a combination of bupivacaine, epinephrine, and dexamethasone designed to manage postoperative pain in pediatric patients undergoing laparoscopic appendectomy. The regimen involves an ultrasound-guided rectus sheath block (RSB) using bupivacaine (a voltage-gated sodium channel blocker) and epinephrine (a vasoconstrictor) to provide regional anesthesia, supplemented by intravenous dexamethasone (a glucocorticoid receptor agonist). Dexamethasone is utilized as an adjunct to prolong the duration of the local anesthetic effect and provide systemic anti-inflammatory benefits. This combination is currently being evaluated in a Phase 2 pilot study (NCT06945263) to assess its efficacy in reducing postoperative opioid requirements and improving recovery outcomes compared to standard local anesthetic infiltration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bupivacaine + epinephrine + dexamethasone (University of British Columbia).